Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-1723
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial ; volume:13 ; number:1 ; day:10 ; month:10 ; year:2022 ; pages:1-12 ; date:12.2022
Nature Communications ; 13, Heft 1 (10.10.2022), 1-12, 12.2022
- Urheber
-
Motzer, Robert J.
Martini, Jean-François
Mu, Xinmeng J.
Staehler, Michael
George, Daniel J.
Valota, Olga
Lin, Xun
Pandha, Hardev S.
Ching, Keith A.
Ravaud, Alain
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-022-33555-8
- URN
-
urn:nbn:de:101:1-2022122721230530472543
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Motzer, Robert J.
- Martini, Jean-François
- Mu, Xinmeng J.
- Staehler, Michael
- George, Daniel J.
- Valota, Olga
- Lin, Xun
- Pandha, Hardev S.
- Ching, Keith A.
- Ravaud, Alain
- SpringerLink (Online service)
Ähnliche Objekte (12)
Anti-angiogenic alternatives to VEGF blockade
Anti-angiogenic therapies in brain metastases
Future options of anti-angiogenic cancer therapy
Correction: Beyond starving cancer: anti-angiogenic therapy
The efficacy of small molecule anti-angiogenic drugs in previously treated Thymic carcinoma
Characterization of anti-angiogenic therapy response in glioblastoma
Anti-angiogenic therapies for advanced esophago-gastric cancer
Perforated Gastric Ulcer Associated with Anti-Angiogenic Therapy
Anti-angiogenic therapy for advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective multicenter study
Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors
Enhancing the anti-angiogenic action of histone deacetylase inhibitors
Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma
Anti-angiogenic alternatives to VEGF blockade
Anti-angiogenic therapies in brain metastases
Future options of anti-angiogenic cancer therapy
Correction: Beyond starving cancer: anti-angiogenic therapy
The efficacy of small molecule anti-angiogenic drugs in previously treated Thymic carcinoma
Characterization of anti-angiogenic therapy response in glioblastoma
Anti-angiogenic therapies for advanced esophago-gastric cancer
Perforated Gastric Ulcer Associated with Anti-Angiogenic Therapy
Anti-angiogenic therapy for advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective multicenter study
Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors
Enhancing the anti-angiogenic action of histone deacetylase inhibitors
Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma
Anti-angiogenic alternatives to VEGF blockade
Anti-angiogenic therapies in brain metastases
Future options of anti-angiogenic cancer therapy
Correction: Beyond starving cancer: anti-angiogenic therapy
The efficacy of small molecule anti-angiogenic drugs in previously treated Thymic carcinoma
Characterization of anti-angiogenic therapy response in glioblastoma
Anti-angiogenic therapies for advanced esophago-gastric cancer
Perforated Gastric Ulcer Associated with Anti-Angiogenic Therapy
Anti-angiogenic therapy for advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective multicenter study
Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors
Enhancing the anti-angiogenic action of histone deacetylase inhibitors